Literature DB >> 15976186

Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro.

Rebekah J Jakel1, Jonathan T Kern, Delinda A Johnson, Jeffrey A Johnson.   

Abstract

Parkinson's disease, a progressive neurodegenerative disorder, is characterized by loss of midbrain dopaminergic neurons. The etiology of sporadic Parkinson's disease is unknown; however, oxidative stress is thought to play a major role in disease pathogenesis. Little is known regarding the transcriptional changes that occur in Parkinson's disease. The antioxidant response element is a cis-acting enhancer sequence that is upstream of many phase II detoxification and antioxidant genes. Here we show that 6-hydroxydopamine, a mitochondrial inhibitor used to model Parkinson's disease, activates the antioxidant response element both in cultured neurons and in the striatum and brainstem of 6-OHDA-lesioned mice. Pretreatment with antioxidants or NMDA receptor antagonists reduced but did not abolish activation. Further induction of this pathway with tert-butylhydroquinone was able to significantly reduce cell death due to 6-OHDA in vitro. These observations indicate that 6-OHDA activates the antioxidant response element through components of oxidative stress, excitotoxicity, and potential structural factors. Further induction of this endogenous defense mechanism may suggest a novel therapeutic venue in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976186     DOI: 10.1093/toxsci/kfi241

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  18 in total

Review 1.  Location, location, location: altered transcription factor trafficking in neurodegeneration.

Authors:  Charleen T Chu; Edward D Plowey; Ying Wang; Vivek Patel; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2007-10       Impact factor: 3.685

2.  Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory function when cultured in spheroids.

Authors:  Jürgen Berg; Manfred Roch; Jennifer Altschüler; Christine Winter; Anne Schwerk; Andreas Kurtz; Barbara Steiner
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739

3.  Perturbations in dopamine synthesis lead to discrete physiological effects and impact oxidative stress response in Drosophila.

Authors:  Marley E Hanna; Andrea Bednářová; Kuntol Rakshit; Anathbandhu Chaudhuri; Janis M O'Donnell; Natraj Krishnan
Journal:  J Insect Physiol       Date:  2015-01-10       Impact factor: 2.354

4.  Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition.

Authors:  Marcus J Calkins; Marcelo R Vargas; Delinda A Johnson; Jeffrey A Johnson
Journal:  Toxicol Sci       Date:  2010-03-08       Impact factor: 4.849

5.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

6.  Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.

Authors:  Marcus J Calkins; Jessica A Townsend; Delinda A Johnson; Jeffrey A Johnson
Journal:  Exp Neurol       Date:  2010-04-18       Impact factor: 5.330

Review 7.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

Review 8.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

9.  Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells.

Authors:  Behrang Alani; Rasoul Salehi; Payam Sadeghi; Mohammad Zare; Fariba Khodagholi; Ehsan Arefian; Mazdak Ganjalikhani Hakemi; Hadi Digaleh
Journal:  J Mol Neurosci       Date:  2014-03       Impact factor: 3.444

Review 10.  The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease.

Authors:  Marcus J Calkins; Delinda A Johnson; Jessica A Townsend; Marcelo R Vargas; James A Dowell; Tracy P Williamson; Andrew D Kraft; Jong-Min Lee; Jiang Li; Jeffrey A Johnson
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.